Phathom Pharmaceuticals, Inc. Other financial activities

Other financial activities of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Other financial activities growth rates and interactive chart.


Highlights and Quick Summary

  • Other financial activities for the quarter ending September 29, 2021 was $7.12 Million (a 49.79% increase compared to previous quarter)
  • Year-over-year quarterly Other financial activities increased by 144.54%
  • Annual Other financial activities for 2020 was $7.34 Million (a -96.78% decrease from previous year)
  • Annual Other financial activities for 2019 was $228 Million (a 456170.0% increase from previous year)
  • Twelve month Other financial activities ending September 29, 2021 was $19.3 Million (a 30.64% increase compared to previous quarter)
  • Twelve month trailing Other financial activities increased by 163.3% year-over-year
Trailing Other financial activities for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$19.3 Million $14.8 Million $11.2 Million $7.34 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Other financial activities of Phathom Pharmaceuticals, Inc.

Most recent Other financial activitiesof PHAT including historical data for past 10 years.

Interactive Chart of Other financial activities of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Other financial activities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $7.12 $4.75 $4.54
2020 $2.91 $2.59 $1.17 $0.67 $7.34
2019 $84.94 $-1.3 $228.14
2018 $0.05

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.